Quote | Medical Intelligence Technologies Inc (OTCMKTS:MDCLF)
Last: | $6.9757 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $6.9757 |
High: | $0 |
Low: | $0 |
Volume: | 2,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Medical Intelligence Technologies Inc (OTCMKTS:MDCLF)
2024-05-08 10:13:13 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call Presentation Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportu...
2024-05-08 07:40:43 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Pos...
Message Board Posts | Medical Intelligence Technologies Inc (OTCMKTS:MDCLF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Medical Intelligence Technologies Inc Company Name:
MDCLF Stock Symbol:
OTCMKTS Market:
Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales. Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting inj...
Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission...
Guidance for 2024 UZEDY Teva’s revenue: ~ $80 million Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed MedinCell (Paris:MEDCL): Access...